Delving into the Latest Updates on Yantai Chuanghe Biotechnology Co., Ltd with Synapse

Overview

Basic Info

Introduction

Yantai Chuanghe Biotechnology Co., Ltd. was established on the 28th of December, 2021. The company's registration is located on Changning Road, Binhai Street, Laishan District, in the city of Yantai, Shandong Province.

Tags

Neoplasms

Urogenital Diseases

Skin and Musculoskeletal Diseases

Small molecule drug

Chemical drugs

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Neoplasms	3
Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Small molecule drug	3
Chemical drugs	1

Top 5 Target	Count

ER x ERα	1

Primary objective: To preliminarily evaluate the effectiveness of different doses of LY01021 during controlled ovarian stimulation in female subjects undergoing assisted reproductive technology. Secondary objective: To preliminarily evaluate the safety of different doses of LY01021 during controlled ovarian stimulation in female subjects undergoing assisted reproductive technology.

Start Date09 Oct 2024

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

CTR20241485

/ CompletedPhase 1

在健康女性受试者中评价食物对LY01021药代动力学特征影响的随机、开放、单次给药、两周期、双交叉设计的I期临床研究

[Translation] A randomized, open-label, single-dose, two-period, double-crossover phase I clinical study to evaluate the effect of food on the pharmacokinetic characteristics of LY01021 in healthy female subjects

评价食物对健康女性受试者单次口服LY01021 80 mg药代动力学特征的影响。

[Translation]

To evaluate the effect of food on the pharmacokinetic characteristics of LY01021 80 mg after a single oral dose in healthy female subjects.

Start Date15 May 2024

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

CTR20234209

/ CompletedPhase 1

在绝经期前健康女性受试者中评价LY01021多次给药的安全性、耐受性、药代动力学及药效学特征的随机、双盲、安慰剂对照、剂量递增的Ⅰ期临床研究

[Translation] A randomized, double-blind, placebo-controlled, dose-escalating Phase I clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of LY01021 in healthy premenopausal female subjects

主要目的：在绝经期前健康女性受试者中评价LY01021多次给药的安全性和耐受性。

[Translation]

Primary objective: To evaluate the safety and tolerability of multiple doses of LY01021 in healthy premenopausal female subjects.

Start Date27 Dec 2023

Sponsor / Collaborator

Yantai Chuanghe Biotechnology Co., Ltd

100 Clinical Results associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

0 Patents (Medical) associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

100 Deals associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

100 Translational Medicine associated with Yantai Chuanghe Biotechnology Co., Ltd

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 30 Apr 2026

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Discovery

1

IND Application

Phase 1

1

Phase 2

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

LPM-7100328	Infertility, Female More	Phase 2
LPM6690176	Advanced Malignant Solid Neoplasm More	Phase 1
CN116804008 ( ER x ERα )Patent Mining	Breast Cancer More	Discovery